Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$7.94 USD
-0.07 (-0.87%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $7.95 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -55.19 | 872.13 | -199.43 | -278.02 | -236.46 |
Depreciation/Amortization & Depletion | 0.10 | 3.04 | 5.92 | 5.72 | 2.99 |
Net Change from Assets/Liabilities | -8.34 | 46.77 | -39.58 | -39.46 | -45.40 |
Net Cash from Discontinued Operations | 0.00 | -1,149.52 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.43 | 40.59 | 25.23 | 61.36 | 40.67 |
Net Cash From Operating Activities | -27.00 | -186.99 | -207.86 | -250.40 | -238.20 |
Property & Equipment | -0.97 | 1.29 | -3.40 | -6.55 | -3.17 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 2.71 | 0.00 | 0.00 | 5.00 |
Investments | -31.72 | 54.87 | 127.89 | 17.27 | -84.88 |
Other Investing Activities | 0.00 | 1,095.13 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -32.70 | 1,154.01 | 124.49 | 10.72 | -83.05 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -198.93 | -131.48 | 102.59 | 135.23 | 3.44 |
Issuance (Repayment) of Debt | 0.00 | -631.60 | -10.73 | 127.86 | -2.15 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 4.28 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -198.93 | -758.81 | 91.86 | 263.09 | 1.29 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -258.63 | 208.21 | 8.50 | 23.40 | -319.96 |
Cash at Beginning of Period | 299.01 | 90.80 | 82.30 | 58.90 | 378.85 |
Cash at End of Period | 40.38 | 299.01 | 90.80 | 82.30 | 58.90 |
Diluted Net EPS | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 |
Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -28.19 | -11.66 | -55.19 | -46.68 | -37.73 |
Depreciation/Amortization & Depletion | -0.07 | 0.08 | 0.10 | 0.12 | 0.09 |
Net Change from Assets/Liabilities | 6.81 | 4.12 | -8.34 | -4.93 | -3.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.02 | 6.45 | 36.43 | 25.35 | 17.57 |
Net Cash From Operating Activities | -5.44 | -1.02 | -27.00 | -26.14 | -23.66 |
Property & Equipment | -0.13 | -0.09 | -0.97 | -0.30 | -0.28 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 14.12 | 17.12 | -31.72 | -31.72 | -31.72 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 14.00 | 17.03 | -32.70 | -32.02 | -32.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1.76 | -1.72 | -198.93 | -168.32 | -136.92 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -1.76 | -1.72 | -198.93 | -168.32 | -136.92 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 6.80 | 14.29 | -258.63 | -226.49 | -192.58 |
Cash at Beginning of Period | 40.38 | 40.38 | 299.01 | 299.01 | 299.01 |
Cash at End of Period | 47.18 | 54.67 | 40.38 | 72.52 | 106.43 |
Diluted Net EPS | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |